Related Experiment Video
Updated: Mar 20, 2026
18:48
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
15.0K
A Promoter Polymorphism in the CD46 Complement Regulatory Protein Gene Is Associated With Acute Renal Allograft
1Department of Surgery, School of Medicine, Kyung Hee University, Republic of Korea.
Transplantation Proceedings
|May 29, 2016
Summary
The CD46 gene promoter polymorphism rs2796267 is associated with reduced risk of acute renal allograft rejection and late acute rejection in Korean kidney transplant patients. This finding may help predict transplant outcomes.
Area of Science:
- Immunogenetics
- Transplantation immunology
- Molecular biology
Background:
- CD46 (complement regulatory protein) is a cell surface receptor crucial for complement and T-cell regulation in organ transplantation.
- Genetic variations in CD46 may influence transplant outcomes, including rejection and graft survival.
Purpose of the Study:
- To investigate the association between CD46 gene promoter polymorphism (rs2796267, -496 A/G) and outcomes of kidney transplantation in Korean patients.
- Specifically, to evaluate the relationship with acute renal allograft rejection (AR), late acute rejection (LAR), and graft loss (GL).
Main Methods:
- Genotyping of the CD46 promoter single nucleotide polymorphism (SNP) rs2796267 using direct sequencing.
- Analysis of transplantation outcomes (AR, LAR, GL) in 334 kidney transplant recipients.
Main Results:
- The rs2796267 SNP showed a significant association with a reduced risk of AR (P=.012) and LAR (P=.041).
- Specific models, including codominant and dominant models, indicated a protective effect of the polymorphism against rejection.
- Allele distribution analysis also revealed a significant association with lower AR and LAR incidence.
Conclusions:
- The CD46 gene promoter polymorphism rs2796267 (-496 A/G) may be a significant genetic factor influencing susceptibility to acute renal allograft rejection in Korean kidney transplant recipients.
- This polymorphism could potentially serve as a predictive marker for transplant outcomes.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
65
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
01:28Kidney Transplant I: Introduction
670
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
670
01:26Kidney Transplant II: Surgical Procedure
733
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
733